Lancaster Medical Group Limited 10940022 false 2025-04-01 2026-03-31 2026-03-31 The principal activity of the company is provision of pharmacy services Digita Accounts Production Advanced 6.30.9574.0 true 10940022 2025-04-01 2026-03-31 10940022 2026-03-31 10940022 core:RetainedEarningsAccumulatedLosses 2026-03-31 10940022 core:CurrentFinancialInstruments 2026-03-31 10940022 core:CurrentFinancialInstruments core:WithinOneYear 2026-03-31 10940022 core:Goodwill 2026-03-31 10940022 core:FurnitureFittingsToolsEquipment 2026-03-31 10940022 core:MotorVehicles 2026-03-31 10940022 core:OtherPropertyPlantEquipment 2026-03-31 10940022 bus:SmallEntities 2025-04-01 2026-03-31 10940022 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 10940022 bus:FilletedAccounts 2025-04-01 2026-03-31 10940022 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 10940022 bus:RegisteredOffice 2025-04-01 2026-03-31 10940022 bus:Director1 2025-04-01 2026-03-31 10940022 bus:Director2 2025-04-01 2026-03-31 10940022 bus:Director4 2025-04-01 2026-03-31 10940022 bus:Director5 2025-04-01 2026-03-31 10940022 bus:Director6 2025-04-01 2026-03-31 10940022 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 10940022 bus:Agent1 2025-04-01 2026-03-31 10940022 core:Goodwill 2025-04-01 2026-03-31 10940022 core:FurnitureFittings 2025-04-01 2026-03-31 10940022 core:FurnitureFittingsToolsEquipment 2025-04-01 2026-03-31 10940022 core:MotorVehicles 2025-04-01 2026-03-31 10940022 core:OtherPropertyPlantEquipment 2025-04-01 2026-03-31 10940022 core:PlantMachinery 2025-04-01 2026-03-31 10940022 core:VehiclesPlantMachinery 2025-04-01 2026-03-31 10940022 countries:EnglandWales 2025-04-01 2026-03-31 10940022 2025-03-31 10940022 core:Goodwill 2025-03-31 10940022 core:FurnitureFittingsToolsEquipment 2025-03-31 10940022 core:MotorVehicles 2025-03-31 10940022 core:OtherPropertyPlantEquipment 2025-03-31 10940022 2024-04-01 2025-03-31 10940022 2025-03-31 10940022 core:RetainedEarningsAccumulatedLosses 2025-03-31 10940022 core:CurrentFinancialInstruments 2025-03-31 10940022 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 10940022 core:Goodwill 2025-03-31 10940022 core:FurnitureFittingsToolsEquipment 2025-03-31 10940022 core:MotorVehicles 2025-03-31 10940022 core:OtherPropertyPlantEquipment 2025-03-31 iso4217:GBP xbrli:pure

REGISTRAR OF COMPANIES

Registration number: 10940022

Lancaster Medical Group Limited

Unaudited Financial Statements

31 March 2026

image-name

 

Lancaster Medical Group Limited

Contents

Accountants' Report

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

4

 

Chartered Accountants' Report to the Board of Directors on the Preparation of the Unaudited Statutory Accounts of
Lancaster Medical Group Limited
for the Year Ended 31 March 2026

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Lancaster Medical Group Limited for the year ended 31 March 2026 as set out on pages 2 to 9 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at http://www.icaew.com/regulation.

This report is made solely to the Board of Directors of Lancaster Medical Group Limited, as a body, in accordance with the terms of our engagement letter dated 6 August 2026. Our work has been undertaken solely to prepare for your approval the accounts of Lancaster Medical Group Limited and state those matters that we have agreed to state to the Board of Directors of Lancaster Medical Group Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Lancaster Medical Group Limited and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Lancaster Medical Group Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and loss of Lancaster Medical Group Limited. You consider that Lancaster Medical Group Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Lancaster Medical Group Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.



Dodd & Co Limited
Chartered Accountants
Clint Mill
Cornmarket
PENRITH
CA11 7HW

15 September 2026

 

Lancaster Medical Group Limited

(Registration number: 10940022)
Balance Sheet as at 31 March 2026

Note

2026
£

2025
£

Fixed assets

 

Intangible assets

4

115,391

173,086

Tangible assets

5

3,113

5,430

 

118,504

178,516

Current assets

 

Stocks

23,390

21,243

Debtors

6

75,779

93,858

Cash at bank and in hand

 

75,237

41,874

 

174,406

156,975

Creditors: Amounts falling due within one year

7

(658,239)

(683,196)

Net current liabilities

 

(483,833)

(526,221)

Net liabilities

 

(365,329)

(347,705)

Capital and reserves

 

Profit and loss account

(365,329)

(347,705)

Total equity

 

(365,329)

(347,705)

 

Lancaster Medical Group Limited

(Registration number: 10940022)
Balance Sheet as at 31 March 2026 (continued)

For the financial year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

•

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

•

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 15 September 2026 and signed on its behalf by:
 

.........................................
A Williams
Director

.........................................
Dr G B Torr
Director

.........................................
Dr A Dickinson
Director

.........................................
Dr M Price
Director

.........................................
Dr R A Carruthers
Director

     
 

Lancaster Medical Group Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
8 Dalton Square
LANCASTER
LA1 1PN

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The company has net liabilities at 31 March 2026 and meets its day to day working capital requirements through normal trading activities and financing provided by Lancaster Medical Practice.The directors consider it appropriate to prepare the financial statements on the going concern basis.

However, should the financing from Lancaster Medical Practice cease, the company may be unable to continue trading, and adjustments would have to be made to reduce the value of assets to their recoverable amounts, to provide for any further liabilities which might arise, and to reclassify fixed assets and long term liabilities as current assets and current liabilities.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when the amount of revenue can be reliably measured; it is probable that future economic benefits will flow to the entity; and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

Lancaster Medical Group Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026 (continued)

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Plant and equipment

20% reducing balance

Motor vehicles

20% reducing balance

Fixtures, fittings and office equipment

20% straight line

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

Straight line over 10 years

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

 

Lancaster Medical Group Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026 (continued)

Trade debtors

Trade debtors are amounts due from customers for the sale of goods or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method where due after more than one year.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

 

Lancaster Medical Group Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026 (continued)

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company during the year, was 6 (2025 - 7).

 

Lancaster Medical Group Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026 (continued)

4

Intangible assets

Goodwill
 £

Total
£

Cost or valuation

At 1 April 2025

576,953

576,953

At 31 March 2026

576,953

576,953

Amortisation

At 1 April 2025

403,867

403,867

Amortisation charge

57,695

57,695

At 31 March 2026

461,562

461,562

Carrying amount

At 31 March 2026

115,391

115,391

At 31 March 2025

173,086

173,086

5

Tangible assets

Plant and equipment
 £

Motor vehicles
 £

Furniture, fittings and office equipment
 £

Total
£

Cost or valuation

At 1 April 2025

307

7,766

2,534

10,607

Disposals

-

(2,930)

-

(2,930)

At 31 March 2026

307

4,836

2,534

7,677

Depreciation

At 1 April 2025

69

4,254

854

5,177

Charge for the year

48

437

507

992

Eliminated on disposal

-

(1,605)

-

(1,605)

At 31 March 2026

117

3,086

1,361

4,564

Carrying amount

At 31 March 2026

190

1,750

1,173

3,113

At 31 March 2025

238

3,512

1,680

5,430

 

Lancaster Medical Group Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026 (continued)

6

Debtors

2026
£

2025
£

Trade debtors

3,373

4,506

Other debtors

72,406

89,352

75,779

93,858

7

Creditors

Note

2026
£

2025
£

Due within one year

 

Loans and borrowings

8

545,624

582,594

Trade creditors

 

94,845

91,672

Corporation tax liability

 

13,003

3,196

Other creditors

 

4,767

5,734

 

658,239

683,196

8

Loans and borrowings

2026
£

2025
£

Current loans and borrowings

Other borrowings

545,624

582,594